On April 1, 2026, the FDA approved Foundayo (orforglipron) — and with it, the rules for oral GLP-1 medications changed. Unlike the Wegovy pill, which requires an empty stomach, limited water, and a 30-minute fast, Foundayo can be taken at any time of day, with or without food and water. That flexibility isn't a minor convenience — it's the kind of difference that determines whether patients actually stay on their medication.
Foundayo is the second oral GLP-1 approved for weight management, following the Wegovy pill (oral semaglutide) in December 2025. But it's a fundamentally different compound — a small-molecule drug rather than a peptide reformulated into a pill — and that molecular difference is what makes the flexibility possible.
The Science: Why Foundayo Is Different
Every other FDA-approved GLP-1 medication on the market — Wegovy, Zepbound, Ozempic, Mounjaro — is based on a peptide, a chain of amino acids. Peptides are fragile. They break down in stomach acid and have poor oral bioavailability, which is why most GLP-1 medications are given as injections. The oral semaglutide pill (Wegovy/Rybelsus) overcomes this by using a special absorption enhancer (SNAC) and requiring strict fasting conditions to protect the peptide during absorption.
Foundayo takes a different approach entirely. Orforglipron is a small-molecule compound — not a peptide. Small molecules are inherently more stable in the digestive system and don't need the same protective measures. The result is a pill that the body can absorb efficiently regardless of food in the stomach, water intake, or time of day.
This isn't just a convenience upgrade. It's a pharmacological distinction that eliminates an entire category of adherence barriers.
The Clinical Data: ATTAIN Trials
Foundayo's approval was based on data from two large Phase 3 trials in the ATTAIN program.
ATTAIN-1 Trial
3,127 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes.
Average body weight reduction at the highest dose (36 mg) over 72 weeks. That's approximately 27 pounds for a typical participant.
Lower doses showed proportionally less weight loss: approximately 7.8% at 6 mg and 9.3% at 12 mg.
ATTAIN-2 Trial
Studied orforglipron in adults with type 2 diabetes. Showed meaningful improvements in hemoglobin A1c (1.3 to 1.6 percentage point reduction) and approximately 8% body weight loss at the highest dose over 40 weeks.
Note: Foundayo is currently approved for chronic weight management, not diabetes. The diabetes indication may come separately.
Putting the numbers in context
Foundayo's 12.4% average weight loss at the highest dose is clinically meaningful — it exceeds the 5% threshold that most clinical guidelines consider significant, and it surpasses what older weight loss medications typically achieve. However, it is somewhat lower than what injectable GLP-1 medications have shown in comparable trials: semaglutide (Wegovy injection) achieved roughly 15% in the STEP trials, and tirzepatide (Zepbound) achieved approximately 20% in the SURMOUNT trials.
This trade-off — somewhat less weight loss in exchange for a flexible daily pill instead of a weekly injection — is a trade-off many patients will find favorable. The best medication is the one you actually take consistently, and a pill with no restrictions is easier to take consistently than either an injection or a pill that requires fasting.
Dosing and Titration
Foundayo uses a structured dose titration schedule designed to minimize gastrointestinal side effects:
Weeks 1–2: 3 mg daily (starting dose)
Weeks 3–4: 6 mg daily
Weeks 5–8: 12 mg daily
Weeks 9–12: 14.5 mg daily
Weeks 13–16: 17.2 mg daily
Weeks 17–20: 24 mg daily (if needed)
Week 21+: 36 mg daily (maximum dose)
The full titration takes approximately 20 weeks — about five months — to reach the maximum 36 mg dose. Your prescriber may adjust this schedule based on your tolerance. Not every patient will need or tolerate the 36 mg dose; some achieve satisfactory results at lower doses.
Pricing
Eli Lilly has set up a savings program for Foundayo that makes the out-of-pocket cost competitive with other GLP-1 options:
Starting doses (3 mg through 12 mg): $149 per month with the Lilly savings card. This covers the titration period.
Maintenance doses (14.5 mg, 17.2 mg, and 36 mg): $299 per month with the savings card.
The savings card is available to eligible commercially insured patients and self-pay patients. Government insurance recipients (Medicare, Medicaid, Tricare) are not eligible for the savings card but may have other coverage options, including the Medicare GLP-1 Bridge program starting July 2026.
Foundayo became available through LillyDirect on April 6, 2026, and rolled out to retail pharmacies and telehealth platforms in the following weeks.
Side Effects
Foundayo's side effect profile is consistent with other GLP-1 receptor agonists. The most common side effects reported in the ATTAIN trials were nausea (the most frequently reported, especially during dose titration), diarrhea, vomiting, constipation, and decreased appetite.
These side effects are typically most prominent during the first few weeks at each new dose level and tend to diminish as the body adjusts. The gradual titration schedule is specifically designed to reduce the frequency and severity of GI side effects.
Serious but less common risks include pancreatitis, gallbladder disease, and potential thyroid effects. Foundayo carries the same boxed warning as other GLP-1 receptor agonists regarding thyroid C-cell tumors. It should not be used by patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Who Should Consider Foundayo
Foundayo may be a particularly good fit for patients who have avoided GLP-1 treatment because of needle aversion (a common and valid reason many people don't start injectable medications), patients who tried the Wegovy pill but found the fasting requirements difficult to maintain consistently, patients who want the simplicity of a daily pill that can fit into any routine, and patients starting GLP-1 treatment for the first time who prefer oral medication over injection.
Foundayo may be less ideal for patients seeking the maximum possible weight loss (injectable semaglutide and tirzepatide have shown higher average weight loss in clinical trials), patients who prefer a once-weekly dosing schedule (Wegovy and Zepbound injections are once-weekly; Foundayo is daily), and patients with a history of severe GI disorders, who should discuss their specific situation with their provider.
How to Access Foundayo
There are several pathways to getting a Foundayo prescription:
Through your existing doctor. Any licensed healthcare provider — primary care physician, nurse practitioner, endocrinologist, obesity medicine specialist — can prescribe Foundayo. If you're interested, raise it at your next visit.
Through LillyDirect. Eli Lilly's direct platform connects you with independent telehealth providers for evaluation and prescription, with medication fulfilled through Lilly's pharmacy network.
Through telehealth platforms. Multiple established telehealth weight loss platforms now offer Foundayo. Check whether the platform prescribes FDA-approved medications (not just compounded options) and confirm Foundayo availability in your state.
At retail pharmacies. Foundayo is available at major pharmacy chains nationwide. You'll need a prescription, which can come from any licensed prescriber.
The Bigger Picture: What Foundayo Means for Oral GLP-1s
Foundayo isn't just one more option in a crowded field. It demonstrates that GLP-1 weight loss treatment doesn't have to involve needles, strict timing rules, or disruption to your daily routine. As the first small-molecule oral GLP-1 for weight management, it opens the door for future compounds with similar flexibility — and several are already in the pipeline.
For the millions of people who could benefit from GLP-1 treatment but haven't started because of needles, complexity, or cost, Foundayo lowers the barrier. That expanded access, combined with the ongoing normalization of pharmacological obesity treatment, is genuinely positive for public health.
The medication isn't perfect — no medication is. Its weight loss results are real but more modest than the top-performing injectables. Its long-term data is still limited. And its pricing, while competitive, still represents a significant ongoing expense for self-pay patients. But as the first truly flexible oral GLP-1, Foundayo marks a meaningful step forward in how we treat obesity.